Rheumatoid arthritis

Hideto Kameda, Tsutomu Takeuchi

Research output: Contribution to journalArticle

Abstract

Pathogenesis of rheumatoid arthritis is likely to implicate anti-citrullinated protein/ peptide antibody(ACPA) and an immunodistortion including abnormal T cell subpopulation. Based on above and other recent findings, new biological agents targeted to inflammatory cytokines such as tocilizumab, activated T cells (abatacept) or B cells (ocrelizumab), as well as new small molecule drugs such as JAK3 inhibitor, are sure to further facilitate remission without impaired activity of daily life in patients with RA. The contribution of Japanese physician-scientists to the progress in rheumatology has been significant as described in this review, and it must be increasingly greater in the near future.

Original languageEnglish
Pages (from-to)495-499
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Volume67
Issue number3
Publication statusPublished - 2009 Mar
Externally publishedYes

Fingerprint

ocrelizumab
Rheumatoid Arthritis
T-Lymphocytes
Biological Factors
Rheumatology
B-Lymphocytes
Cytokines
Physicians
Peptides
Antibodies
Pharmaceutical Preparations
Proteins
Abatacept
tocilizumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rheumatoid arthritis. / Kameda, Hideto; Takeuchi, Tsutomu.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 67, No. 3, 03.2009, p. 495-499.

Research output: Contribution to journalArticle

@article{6598e83d39344c31b0f5d88ebfe6b39e,
title = "Rheumatoid arthritis",
abstract = "Pathogenesis of rheumatoid arthritis is likely to implicate anti-citrullinated protein/ peptide antibody(ACPA) and an immunodistortion including abnormal T cell subpopulation. Based on above and other recent findings, new biological agents targeted to inflammatory cytokines such as tocilizumab, activated T cells (abatacept) or B cells (ocrelizumab), as well as new small molecule drugs such as JAK3 inhibitor, are sure to further facilitate remission without impaired activity of daily life in patients with RA. The contribution of Japanese physician-scientists to the progress in rheumatology has been significant as described in this review, and it must be increasingly greater in the near future.",
author = "Hideto Kameda and Tsutomu Takeuchi",
year = "2009",
month = "3",
language = "English",
volume = "67",
pages = "495--499",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "3",

}

TY - JOUR

T1 - Rheumatoid arthritis

AU - Kameda, Hideto

AU - Takeuchi, Tsutomu

PY - 2009/3

Y1 - 2009/3

N2 - Pathogenesis of rheumatoid arthritis is likely to implicate anti-citrullinated protein/ peptide antibody(ACPA) and an immunodistortion including abnormal T cell subpopulation. Based on above and other recent findings, new biological agents targeted to inflammatory cytokines such as tocilizumab, activated T cells (abatacept) or B cells (ocrelizumab), as well as new small molecule drugs such as JAK3 inhibitor, are sure to further facilitate remission without impaired activity of daily life in patients with RA. The contribution of Japanese physician-scientists to the progress in rheumatology has been significant as described in this review, and it must be increasingly greater in the near future.

AB - Pathogenesis of rheumatoid arthritis is likely to implicate anti-citrullinated protein/ peptide antibody(ACPA) and an immunodistortion including abnormal T cell subpopulation. Based on above and other recent findings, new biological agents targeted to inflammatory cytokines such as tocilizumab, activated T cells (abatacept) or B cells (ocrelizumab), as well as new small molecule drugs such as JAK3 inhibitor, are sure to further facilitate remission without impaired activity of daily life in patients with RA. The contribution of Japanese physician-scientists to the progress in rheumatology has been significant as described in this review, and it must be increasingly greater in the near future.

UR - http://www.scopus.com/inward/record.url?scp=65649108118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649108118&partnerID=8YFLogxK

M3 - Article

C2 - 19280922

AN - SCOPUS:65649108118

VL - 67

SP - 495

EP - 499

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 3

ER -